Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis

Gut

Volumn 65, Issue 12, 2016, Pages 1973-1980

  Mima, Kosuke ^a   Nishihara, Reiko ^a,b   Qian, Zhi Rong ^a   Cao, Yin ^b   Sukawa, Yasutaka ^a   Nowak, Jonathan A ^c   Yang, Juhong ^a,d   Dou, Ruoxu ^a   Masugi, Yohei ^a   Song, Mingyang ^b   Kostic, Aleksandar D ^b,e,f   Giannakis, Marios ^a,c,e   Bullman, Susan ^a,e   Milner, Danny A ^b,c   Baba, Hideo ^g   Giovannucci, Edward L ^a,b   Garraway, Levi A ^a,c,e   Freeman, Gordon J ^a,c   Dranoff, Glenn ^a,c,h   Garrett, Wendy S ^a,b,e   Huttenhower, Curtis ^b,e,f   Meyerson, Matthew ^a,c,e   Meyerhardt, Jeffrey A ^a   Chan, Andrew T ^a,f   Fuchs, Charles S ^a   Ogino, Shuji ^a,b,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g KUMAMOTO UNIVERSITY   (Japan)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

CANCER EPIDEMIOLOGY; COLONIC BACTERIA; COLONIC MICROFLORA; COLORECTAL CANCER; INTESTINAL BACTERIA

Indexed keywords

ANTIBIOTIC AGENT; B RAF KINASE; PROBIOTIC AGENT; KRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

AGED; ARTICLE; BRAF GENE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; FUSOBACTERIUM NUCLEATUM; GENE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INTESTINE FLORA; LONG INTERSPERSED REPEAT; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; CANCER STAGING; CARCINOMA; COLORECTAL TUMOR; FACTUAL DATABASE; FOLLOW UP; GENETICS; KAPLAN MEIER METHOD; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MUTATION; PATHOGENICITY; PATHOLOGY; PHENOTYPE; PROGNOSIS;

AGED; BIOMARKERS, TUMOR; CARCINOMA; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; FUSOBACTERIUM NUCLEATUM; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RESEARCH DESIGN;

EID: 84940055522     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310101     Document Type: Article

References (52)

1. McLean MH, Dieguez D Jr, Miller LM, et al. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut 2015;64:332-41.
2. Garrett WS. Cancer and the microbiota. Science 2015;348:80-6.
3. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014;12:661-72.
4. Arthur JC, Gharaibeh RZ, Muhlbauer M, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun 2014;5:4724.
5. Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014;74:1311-18.
6. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292-8.
7. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22:299-306.
8. Belcheva A, Irrazabal T, Robertson SJ, et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 2014;158:288-99.
9. Prorok-Hamon M, Friswell MK, Alswied A, et al. Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut 2014;63:761-70.
10. Cougnoux A, Dalmasso G, Martinez R, et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 2014;63:1932-42.
11. Wang X, Yang Y, Huycke MM. Commensal bacteria drive endogenous transformation and tumour stem cell marker expression through a bystander effect. Gut 2015;64:459-68.
12. Piazzi G, D'Argenio G, Prossomariti A, et al. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. Int J Cancer 2014;135:2004-13.
13. Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA 2014;111:18321-6.
14. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-54.
15. McCoy AN, Araujo-Perez F, Azcarate-Peril A, et al. Fusobacterium is associated with colorectal adenomas. PLoS ONE 2013;8:e53653.
16. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207-15.
17. Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015;137:1258-68.
18. Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195-206.
19. Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015;42:344-55.
20. Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014;33:1381-90.
21. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol 2015;1:653-61.
22. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
23. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-105.
24. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer: a tale of two sides or a continuum? Gut 2012;61:794-7.
25. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
26. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008;122:2767-73.
27. Irahara N, Nosho K, Baba Y, et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn 2010;12:177-83.
28. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-17.
29. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007;9:305-14.
30. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-21.
31. Imamura Y, Lochhead P, Yamauchi M, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 2014;13:135.
32. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-41.
33. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012;18:2257-68.
34. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013;26:465-84.
35. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014;15:317-28.
36. Win AK, Buchanan DD, Rosty C, et al. Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives. Gut 2015;64:101-10.
37. Tillmans LS, Vierkant RA, Wang AH, et al. Associations between cigarette smoking, hormone therapy, and folate intake with incident colorectal cancer by TP53 protein expression level in a population-based cohort of older women. Cancer Epidemiol Biomarkers Prev 2014;23:350-5.
38. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-85.
39. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015;148:77-87.e72.
40. Shiovitz S, Bertagnolli MM, Renfro LA, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 2014;147:637-45.
41. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
42. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013;105:1151-6.
43. Seppala TT, Bohm JP, Friman M, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer 2015;112:1966-75.
44. Manceau G, Marisa L, Boige V, et al. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. Cancer Med 2015;4:371-82.
45. Inamura K, Yamauchi M, Nishihara R, et al. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst 2014;106:pii: dju195.
46. Ahn JB, Chung WB, Maeda O, et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2011;117:1847-54.
47. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
48. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
49. Bishehsari F, Mahdavinia M, Vacca M, et al. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol 2014;20:6055-72.
50. Epplein M, Bostick RM, Mu L, et al. Challenges and opportunities in international molecular cancer prevention research: an ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. Cancer Epidemiol Biomarkers Prev 2014;23:2613-17.
51. Campbell PT, Newton CC, Newcomb PA, et al. Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. Cancer Epidemiol Biomarkers Prev 2015;24:1229-38.
52. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9(Suppl 5):S1-32; quiz S33.